The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Digital Dermoscopy and Monitoring

Dermatoscopic imaging combined with digital photography and computerized analysis enabling longitudinal follow-up of high-risk patients with multiple atypical nevi for early melanoma detection through sequential digital dermoscopy imaging (SDDI) and total body photography (TBP).

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Digital Dermoscopy and Monitoring?

Digital dermoscopy (digital dermatoscopy, computer-assisted dermoscopy, dermoscopy with digital monitoring) is the integration of dermatoscopic examination with digital image capture, storage, and computer-assisted comparison for longitudinal monitoring of pigmented and non-pigmented skin lesions. Originally introduced by Stolz et al in 1990s, it has evolved into sophisticated total body photography (TBP) systems and AI-assisted analysis platforms in 2020s.

Components: 1) Dermatoscope (10-50x magnification, polarized or non-polarized illumination, immersion fluid contact); 2) Digital camera (high-resolution DSLR, smartphone with adapter, dedicated dermatoscopy camera 12-50 megapixel); 3) Image management software (FotoFinder Bodystudio ATBM, MoleMax HD, DermaGraphix, MoleScope, Skin Analytics); 4) Total body photography system (24-100 cameras simultaneously imaging entire skin surface, Vectra WB360, Canfield Vectra); 5) AI-assisted analysis (deep learning algorithms, convolutional neural networks for melanoma detection, MetaOptima MoleScope DermEngine, FotoFinder Moleanalyzer Pro AI).

Methodology: 1) Total body photography (TBP) baseline at first visit (24+ standardized poses, anatomical mapping of all nevi and skin lesions); 2) Selection of high-risk lesions (atypical, large > 5-6 mm, changing) for sequential digital dermoscopy imaging (SDDI); 3) Short-term SDDI (3-month follow-up for suspicious lesions — atypical or melanocytic with mild atypia; if change detected, excise; if stable, continue surveillance); 4) Long-term SDDI (6-12 month follow-up for stable atypical nevi); 5) Comparison software identifies new lesions, missing lesions, changes in size/color/pattern; 6) AI scoring (FotoFinder Moleanalyzer Pro, MoleMap, SkinVision) flags suspicious lesions for clinical review.

Symptoms

Patient with multiple (> 50-100) melanocytic nevi (multiple atypical nevi syndrome, MANS)
Family history of melanoma (familial atypical multiple mole melanoma syndrome — FAMMM, CDKN2A or CDK4 gene mutation)
Personal history of melanoma (lifetime second melanoma risk 5-10 percent)
Multiple atypical/dysplastic nevi (5+ atypical clinical features)
Patient anxiety with normal nevi requiring reassurance through documented surveillance
Difficult-to-monitor patients (immobile, multiple nevi, hard-to-see locations)
Suspected slowly-changing melanoma where short-term monitoring may aid decision
Pre-pregnancy or pre-immunosuppression baseline documentation

Risk Factors

False reassurance with stable but malignant lesion (e.g. nodular melanoma develops vertically without horizontal change)
Patient non-compliance with follow-up appointments
Cost (TBP system $50,000-$200,000, ongoing software subscription, dermatologist time)
Equipment availability limited (specialized centers only)
Image quality variability (lighting, positioning, patient cooperation)
Storage and data security (PHI protection, GDPR/HIPAA compliance)
AI algorithm limitations (training data bias, false positives, false negatives)
Sun exposure between visits altering nevus appearance (camouflages true changes)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Personal history of melanoma (annual TBP and SDDI recommended)
  • Family history of melanoma in 2+ first-degree relatives (genetic counseling, TBP)
  • Multiple atypical nevi (5+ atypical features) — biannual SDDI recommended
  • Numerous melanocytic nevi (> 50-100 lesions) increasing surveillance complexity
  • Genetic syndromes (xeroderma pigmentosum, Li-Fraumeni, BRCA2 mutation carriers)
  • Immunosuppression (organ transplant, HIV, immunosuppressive medication)
  • New, changing, or 'ugly duckling' nevus on routine self-exam
  • Anxiety regarding multiple nevi requiring objective documentation

Treatment Methods

01
Initial consultation and risk assessment: detailed personal and family melanoma history, total skin examination by dermatologist, identification of atypical nevi (asymmetry, irregular border, color variegation, diameter > 6 mm, evolution), genetic testing if FAMMM suspected (CDKN2A, CDK4, BAP1), photodamage assessment (Fitzpatrick skin type, prior sunburns, occupational sun exposure)
02
Total body photography (TBP) baseline: standardized 24+ pose protocol covering all skin surfaces (anterior, posterior, lateral, head and neck, hands, feet, scalp, mucous membranes), high-resolution images (12-50 MP), consistent lighting (cross-polarization or studio strobes), immediate quality control review, image archiving on secure server (HIPAA/GDPR compliant), patient receives copy on USB or secure portal access
03
Sequential digital dermoscopy imaging (SDDI): select up to 50-100 atypical nevi for digital dermoscopy capture (polarized contact dermatoscopy at 10-30x magnification with FotoFinder Studio, MoleMax HD, or smartphone with adapter Heine Delta 30, 3Gen DermLite DL5); standardized image (centered, in focus, ruler scale) saved with patient demographics, anatomical site, lesion characteristics; baseline assessment by 7-point checklist (Argenziano), 3-point checklist (asymmetry, atypical network, blue-white veil), Menzies criteria, ABCD rule, or pattern analysis
04
Short-term monitoring (3-month follow-up): re-image lesions classified as 'suspicious but not biopsy-required' — atypical with mild atypia, no diagnostic features of melanoma; comparison software (FotoFinder Compare, MoleMax Comparator) overlays old and new images, highlights changes in size, color, structure; if change detected (asymmetric enlargement, structural change, color asymmetry, vascular changes) — excise immediately; if stable for 3 months — long-term surveillance (12 months)
05
Long-term monitoring (6-12 month follow-up): annual TBP and SDDI for high-risk patients, biannual for very-high-risk (familial melanoma, multiple prior primary melanomas); detection of new lesions (compared with baseline TBP), missing lesions (regression — possible melanoma), and changes in existing lesions
06
Excision criteria: any new lesion not present at baseline (especially in adults > 30 years), any lesion with documented change on SDDI, lesion with diagnostic dermoscopic features of melanoma (atypical pigment network, blue-white veil, regression structures > 50 percent, multiple colors > 5, atypical vessels, asymmetric structures), nodular lesion (vertical growth without horizontal change — caution with monitoring), patient or family preference
07
Outcomes and limitations: SDDI reduces unnecessary excisions by 30-70 percent (compared with traditional examination), increases melanoma detection rates (in situ melanoma proportion increases), detects melanomas thinner than spontaneous detection (Breslow thickness < 1 mm); limitations include 'fast-growing melanoma' (nodular melanoma may progress between visits, total time to TBP-detected melanoma 6-12 months), false-stable interpretation, patient-dependent compliance, cost and access limitations; AI assistance (FotoFinder Moleanalyzer Pro, SkinVision, MetaOptima DermEngine) emerging with promising sensitivity 90-95 percent and specificity 80-90 percent
08
Patient education and self-monitoring: monthly self-skin examination, ABCDE criteria education, photographic record of suspicious lesions on smartphone (MoleScope, SkinVision app), sun protection (SPF 30+ daily, avoidance of midday sun, protective clothing), avoidance of tanning beds (IARC group 1 carcinogen), monthly self-exam aided by partner for back examination

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.